company background image
AVTX

Avalo Therapeutics NasdaqCM:AVTX Stock Report

Last Price

US$5.36

Market Cap

US$50.5m

7D

36.7%

1Y

-83.9%

Updated

15 Aug, 2022

Data

Company Financials +
AVTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

AVTX Stock Overview

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.

Avalo Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Avalo Therapeutics
Historical stock prices
Current Share PriceUS$5.36
52 Week HighUS$38.88
52 Week LowUS$2.42
Beta1.42
1 Month Change16.52%
3 Month Change46.35%
1 Year Change-83.88%
3 Year Change-87.99%
5 Year Change-26.78%
Change since IPO-88.83%

Recent News & Updates

Shareholder Returns

AVTXUS BiotechsUS Market
7D36.7%1.4%3.6%
1Y-83.9%-19.6%-9.6%

Return vs Industry: AVTX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: AVTX underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is AVTX's price volatile compared to industry and market?
AVTX volatility
AVTX Average Weekly Movement18.6%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: AVTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: AVTX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201143Garry Neilhttps://www.avalotx.com

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn’s disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still’s disease, including adult-onset still’s disease and systemic juvenile idiopathic arthritis.

Avalo Therapeutics, Inc. Fundamentals Summary

How do Avalo Therapeutics's earnings and revenue compare to its market cap?
AVTX fundamental statistics
Market CapUS$50.46m
Earnings (TTM)-US$71.64m
Revenue (TTM)US$3.78m

13.4x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVTX income statement (TTM)
RevenueUS$3.78m
Cost of RevenueUS$32.18m
Gross Profit-US$28.40m
Other ExpensesUS$43.24m
Earnings-US$71.64m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-7.61
Gross Margin-752.40%
Net Profit Margin-1,897.75%
Debt/Equity Ratio-314.5%

How did AVTX perform over the long term?

See historical performance and comparison